REPL Faces Pressure After FDA Issues Second Complete Response Letter
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2026
0mins
Source: stocktwits
- Regulatory Pressure on REPL: REPL's stock plummeted 64% after the FDA issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with nivolumab for anti-PD-1-failed melanoma, highlighting a lack of alignment with the FDA and prompting widespread analyst downgrades across Wall Street.
- HOTH Financing Impact: HOTH's stock declined 1% following the announcement of a $2 million stock offering priced at $0.70 per share, overshadowing positive pipeline updates for its HT-001 therapy, which showed significant efficacy in treating skin toxicities, indicating market concerns over dilution.
- ONCO's Stock Slide: ONCO's shares fell 27% after implementing a 1-for-5 reverse stock split to comply with Nasdaq's minimum bid price requirement, despite ongoing efforts to acquire Realbotix in an all-stock deal, reflecting investor anxiety over compliance pressures.
- Retail Investor Sentiment: Retail sentiment on Stocktwits showed REPL as 'bearish' while HOTH and ONCO were 'extremely bullish', indicating a divergence in market sentiment despite all three stocks underperforming the broader XLV ETF over the past year, with declines of 77%, 36%, and 97% respectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REPL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REPL
Wall Street analysts forecast REPL stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 10.000
Low
3.00
Averages
11.43
High
18.00
Current: 10.000
Low
3.00
Averages
11.43
High
18.00
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UniQure to Seek FDA Approval for Huntington's Gene Therapy
- New FDA Guidance: UniQure learned in a recent meeting that a three-year analysis from a Phase 1/2 study would support accelerated approval for its Huntington's disease gene therapy, marking a significant turnaround after previous criticisms.
- Clinical Data Reversal: Although the FDA previously indicated that UniQure's clinical trial data was insufficient for application support, the new guidance reflects a shift in FDA policy, potentially bringing renewed hope for rare disease drug development.
- Strong Market Reaction: Following the announcement, UniQure's shares surged 70%, indicating investor optimism about the company's future prospects, especially with FDA backing, which could rapidly increase demand for its gene therapy.
- Commitment to Further Research: UniQure has pledged to align with the FDA on study design before submitting its application, including comparing the treatment to current standard care, ensuring the therapy's efficacy and laying the groundwork for future market introduction.
See More
UniQure to Seek Approval for Huntington's Gene Therapy
- FDA Approval Guidance: UniQure plans to submit its application for Huntington's gene therapy to the FDA in Q3, following a meeting where the FDA indicated that a three-year analysis from a Phase 1/2 study would support accelerated approval, marking a significant shift in regulatory stance.
- Clinical Trial Data Controversy: Despite previous criticisms from former FDA leaders regarding UniQure's clinical trial data, the therapy demonstrated a 75% reduction in disease progression in a Phase 1/2 trial, suggesting its efficacy warrants further validation.
- Stock Surge: Following the announcement of its application plans, UniQure's shares soared 70% on Wednesday, reflecting market optimism about the therapy's prospects and investor confidence in the new FDA guidance.
- Future Research Commitment: UniQure is committed to conducting a controlled study comparing its treatment to the current standard of care, with plans to finalize the study design before submitting its application to ensure compliance with FDA requirements.
See More
Replimune's Cancer Immunotherapy Shows Promising Early Data
- Tumor Shrinkage Observed: Replimune noted tumor shrinkage in both injected and non-injected lesions during the RP2 trial, indicating that RP2 can trigger a systemic anti-tumor immune response, thus providing new treatment hope for patients.
- Impressive Efficacy Data: The response rate for RP2 alone was 19%, while the combination with Nivolumab achieved a 19.1% response rate, with nearly 49% of patients maintaining disease control, showcasing the therapy's potential in treating advanced tumors.
- FDA Review Priority: The FDA has decided to prioritize the review of Replimune's application, citing a lack of treatment options for patients with advanced melanoma, reigniting market confidence after two previous rejections.
- Earnings Forecast and Market Reaction: Although a fourth-quarter loss of $0.72 per share is expected, slightly better than last year's $0.82, Replimune's stock surged 13% in pre-market trading, reflecting investor optimism about the company's future performance.
See More
Replimune Receives FDA Support for BLA Resubmission
- BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
- Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
- Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
- Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.
See More
Replimune Presents Final Data for RP2 Oncolytic Therapy
- Clinical Trial Results: At the 2026 American Society of Clinical Oncology annual meeting, Replimune presented final Phase 1 data for RP2 alone and in combination with nivolumab, showing a 19.0% objective response rate in 85 heavily pretreated patients with advanced solid tumors, indicating its potential in treating late-stage cancers.
- Combination Therapy Efficacy: The combination of RP2 with nivolumab achieved a 19.1% objective response rate and a disease control rate of 48.9%, highlighting the clinical significance of this combination in improving patient survival, particularly in uveal melanoma patients.
- Good Tolerability: Both RP2 monotherapy and its combination with nivolumab demonstrated good tolerability with no unexpected toxicities and no Grade 4 or 5 treatment-related adverse events, indicating a safety advantage for this therapy.
- Immune Response Mechanism: The study revealed that RP2 reprograms the tumor microenvironment from
See More
Replimune Reports Landmark Three-Year Survival Data
- Clinical Trial Results: Replimune presented three-year survival data from its IGNYTE trial at the 2026 ASCO annual meeting, revealing that nearly half of treated patients were alive at three years, underscoring the durability and effectiveness of the treatment.
- Survival and Response Rates: The combination therapy achieved a median overall survival of 32.9 months, with an objective response rate of 33.6% and a median duration of response of 24.8 months, indicating that almost 45% of responders maintained their response at three years, showcasing broad applicability among patients.
- Safety Profile Analysis: The regimen demonstrated consistent survival benefits across key patient subgroups and maintained a favorable safety profile, primarily consisting of Grade 1-2 side effects with no new safety signals, further enhancing its clinical application potential.
- Company Development Strategy: Founded in 2015, Replimune is advancing its RPx platform to develop versatile oncolytic immunotherapies that can be used alone or in combination with other treatments, marking significant innovation progress in the field of cancer therapy.
See More
UniQure to Seek FDA Approval for Huntington's Gene Therapy
- New FDA Guidance: UniQure learned in a recent meeting that a three-year analysis from a Phase 1/2 study would support accelerated approval for its Huntington's disease gene therapy, marking a significant turnaround after previous criticisms.
- Clinical Data Reversal: Although the FDA previously indicated that UniQure's clinical trial data was insufficient for application support, the new guidance reflects a shift in FDA policy, potentially bringing renewed hope for rare disease drug development.
- Strong Market Reaction: Following the announcement, UniQure's shares surged 70%, indicating investor optimism about the company's future prospects, especially with FDA backing, which could rapidly increase demand for its gene therapy.
- Commitment to Further Research: UniQure has pledged to align with the FDA on study design before submitting its application, including comparing the treatment to current standard care, ensuring the therapy's efficacy and laying the groundwork for future market introduction.
See More
UniQure to Seek Approval for Huntington's Gene Therapy
- FDA Approval Guidance: UniQure plans to submit its application for Huntington's gene therapy to the FDA in Q3, following a meeting where the FDA indicated that a three-year analysis from a Phase 1/2 study would support accelerated approval, marking a significant shift in regulatory stance.
- Clinical Trial Data Controversy: Despite previous criticisms from former FDA leaders regarding UniQure's clinical trial data, the therapy demonstrated a 75% reduction in disease progression in a Phase 1/2 trial, suggesting its efficacy warrants further validation.
- Stock Surge: Following the announcement of its application plans, UniQure's shares soared 70% on Wednesday, reflecting market optimism about the therapy's prospects and investor confidence in the new FDA guidance.
- Future Research Commitment: UniQure is committed to conducting a controlled study comparing its treatment to the current standard of care, with plans to finalize the study design before submitting its application to ensure compliance with FDA requirements.
See More
Replimune's Cancer Immunotherapy Shows Promising Early Data
- Tumor Shrinkage Observed: Replimune noted tumor shrinkage in both injected and non-injected lesions during the RP2 trial, indicating that RP2 can trigger a systemic anti-tumor immune response, thus providing new treatment hope for patients.
- Impressive Efficacy Data: The response rate for RP2 alone was 19%, while the combination with Nivolumab achieved a 19.1% response rate, with nearly 49% of patients maintaining disease control, showcasing the therapy's potential in treating advanced tumors.
- FDA Review Priority: The FDA has decided to prioritize the review of Replimune's application, citing a lack of treatment options for patients with advanced melanoma, reigniting market confidence after two previous rejections.
- Earnings Forecast and Market Reaction: Although a fourth-quarter loss of $0.72 per share is expected, slightly better than last year's $0.82, Replimune's stock surged 13% in pre-market trading, reflecting investor optimism about the company's future performance.
See More
Replimune Receives FDA Support for BLA Resubmission
- BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
- Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
- Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
- Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.
See More
Replimune Presents Final Data for RP2 Oncolytic Therapy
- Clinical Trial Results: At the 2026 American Society of Clinical Oncology annual meeting, Replimune presented final Phase 1 data for RP2 alone and in combination with nivolumab, showing a 19.0% objective response rate in 85 heavily pretreated patients with advanced solid tumors, indicating its potential in treating late-stage cancers.
- Combination Therapy Efficacy: The combination of RP2 with nivolumab achieved a 19.1% objective response rate and a disease control rate of 48.9%, highlighting the clinical significance of this combination in improving patient survival, particularly in uveal melanoma patients.
- Good Tolerability: Both RP2 monotherapy and its combination with nivolumab demonstrated good tolerability with no unexpected toxicities and no Grade 4 or 5 treatment-related adverse events, indicating a safety advantage for this therapy.
- Immune Response Mechanism: The study revealed that RP2 reprograms the tumor microenvironment from
See More
Replimune Reports Landmark Three-Year Survival Data
- Clinical Trial Results: Replimune presented three-year survival data from its IGNYTE trial at the 2026 ASCO annual meeting, revealing that nearly half of treated patients were alive at three years, underscoring the durability and effectiveness of the treatment.
- Survival and Response Rates: The combination therapy achieved a median overall survival of 32.9 months, with an objective response rate of 33.6% and a median duration of response of 24.8 months, indicating that almost 45% of responders maintained their response at three years, showcasing broad applicability among patients.
- Safety Profile Analysis: The regimen demonstrated consistent survival benefits across key patient subgroups and maintained a favorable safety profile, primarily consisting of Grade 1-2 side effects with no new safety signals, further enhancing its clinical application potential.
- Company Development Strategy: Founded in 2015, Replimune is advancing its RPx platform to develop versatile oncolytic immunotherapies that can be used alone or in combination with other treatments, marking significant innovation progress in the field of cancer therapy.
See More
